The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PD-L1 Biomarker Testing Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The PD-L1 Biomarker Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global PD-L1 Biomarker Testing market size is estimated to be worth US$ 1513.1 million in 2021 and is forecast to a readjusted size of USD 13730 million by 2028 with a CAGR of 37.0% during review period. Hospital accounting for % of the PD-L1 Biomarker Testing global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While PD-L1 (22C3) segment is altered to a % CAGR between 2022 and 2028.
Global key companies of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PD-L1 Biomarker Testing market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Market segment by Application, can be divided into
Hospital
Diagnostic Center
Others
Market segment by players, this report covers
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe PD-L1 Biomarker Testing product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of PD-L1 Biomarker Testing, with revenue, gross margin and global market share of PD-L1 Biomarker Testing from 2019 to 2022.
Chapter 3, the PD-L1 Biomarker Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and PD-L1 Biomarker Testing market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe PD-L1 Biomarker Testing research findings and conclusion, appendix and data source.
Geographical Area
Global
The PD-L1 Biomarker Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global PD-L1 Biomarker Testing market size is estimated to be worth US$ 1513.1 million in 2021 and is forecast to a readjusted size of USD 13730 million by 2028 with a CAGR of 37.0% during review period. Hospital accounting for % of the PD-L1 Biomarker Testing global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While PD-L1 (22C3) segment is altered to a % CAGR between 2022 and 2028.
Global key companies of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PD-L1 Biomarker Testing market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Market segment by Application, can be divided into
Hospital
Diagnostic Center
Others
Market segment by players, this report covers
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe PD-L1 Biomarker Testing product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of PD-L1 Biomarker Testing, with revenue, gross margin and global market share of PD-L1 Biomarker Testing from 2019 to 2022.
Chapter 3, the PD-L1 Biomarker Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and PD-L1 Biomarker Testing market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe PD-L1 Biomarker Testing research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of PD-L1 Biomarker Testing
1.2 Classification of PD-L1 Biomarker Testing by Type
1.2.1 Overview: Global PD-L1 Biomarker Testing Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global PD-L1 Biomarker Testing Revenue Market Share by Type in 2021
1.2.3 PD-L1 (22C3)
1.2.4 PD-L1(28-8)
1.2.5 PD-L1 (SP142)
1.2.6 PD-L1 (SP263)
1.2.7 Other
1.3 Global PD-L1 Biomarker Testing Market by Application
1.3.1 Overview: Global PD-L1 Biomarker Testing Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Global PD-L1 Biomarker Testing Market Size & Forecast
1.5 Global PD-L1 Biomarker Testing Market Size and Forecast by Region
1.5.1 Global PD-L1 Biomarker Testing Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global PD-L1 Biomarker Testing Market Size by Region, (2017-2022)
1.5.3 North America PD-L1 Biomarker Testing Market Size and Prospect (2017-2028)
1.5.4 Europe PD-L1 Biomarker Testing Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific PD-L1 Biomarker Testing Market Size and Prospect (2017-2028)
1.5.6 South America PD-L1 Biomarker Testing Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa PD-L1 Biomarker Testing Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 PD-L1 Biomarker Testing Market Drivers
1.6.2 PD-L1 Biomarker Testing Market Restraints
1.6.3 PD-L1 Biomarker Testing Trends Analysis
2 Company Profiles
2.1 Agilent Technologies
2.1.1 Agilent Technologies Details
2.1.2 Agilent Technologies Major Business
2.1.3 Agilent Technologies PD-L1 Biomarker Testing Product and Solutions
2.1.4 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Agilent Technologies Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche PD-L1 Biomarker Testing Product and Solutions
2.2.4 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Roche Recent Developments and Future Plans
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck PD-L1 Biomarker Testing Product and Solutions
2.3.4 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Merck Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Product and Solutions
2.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca PD-L1 Biomarker Testing Product and Solutions
2.5.4 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Ono Pharmaceutical
2.6.1 Ono Pharmaceutical Details
2.6.2 Ono Pharmaceutical Major Business
2.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Product and Solutions
2.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Ono Pharmaceutical Recent Developments and Future Plans
2.7 Regeneron
2.7.1 Regeneron Details
2.7.2 Regeneron Major Business
2.7.3 Regeneron PD-L1 Biomarker Testing Product and Solutions
2.7.4 Regeneron PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Regeneron Recent Developments and Future Plans
2.8 Innovent
2.8.1 Innovent Details
2.8.2 Innovent Major Business
2.8.3 Innovent PD-L1 Biomarker Testing Product and Solutions
2.8.4 Innovent PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Innovent Recent Developments and Future Plans
2.9 Hengrui Medicine
2.9.1 Hengrui Medicine Details
2.9.2 Hengrui Medicine Major Business
2.9.3 Hengrui Medicine PD-L1 Biomarker Testing Product and Solutions
2.9.4 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Hengrui Medicine Recent Developments and Future Plans
2.10 Junshi Biosciences
2.10.1 Junshi Biosciences Details
2.10.2 Junshi Biosciences Major Business
2.10.3 Junshi Biosciences PD-L1 Biomarker Testing Product and Solutions
2.10.4 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Junshi Biosciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PD-L1 Biomarker Testing Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 PD-L1 Biomarker Testing Players Market Share in 2021
3.2.2 Top 10 PD-L1 Biomarker Testing Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 PD-L1 Biomarker Testing Players Head Office, Products and Services Provided
3.4 PD-L1 Biomarker Testing Mergers & Acquisitions
3.5 PD-L1 Biomarker Testing New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global PD-L1 Biomarker Testing Revenue and Market Share by Type (2017-2022)
4.2 Global PD-L1 Biomarker Testing Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global PD-L1 Biomarker Testing Revenue Market Share by Application (2017-2022)
5.2 Global PD-L1 Biomarker Testing Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America PD-L1 Biomarker Testing Revenue by Type (2017-2028)
6.2 North America PD-L1 Biomarker Testing Revenue by Application (2017-2028)
6.3 North America PD-L1 Biomarker Testing Market Size by Country
6.3.1 North America PD-L1 Biomarker Testing Revenue by Country (2017-2028)
6.3.2 United States PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
6.3.3 Canada PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
6.3.4 Mexico PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe PD-L1 Biomarker Testing Revenue by Type (2017-2028)
7.2 Europe PD-L1 Biomarker Testing Revenue by Application (2017-2028)
7.3 Europe PD-L1 Biomarker Testing Market Size by Country
7.3.1 Europe PD-L1 Biomarker Testing Revenue by Country (2017-2028)
7.3.2 Germany PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
7.3.3 France PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
7.3.4 United Kingdom PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
7.3.5 Russia PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
7.3.6 Italy PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific PD-L1 Biomarker Testing Revenue by Type (2017-2028)
8.2 Asia-Pacific PD-L1 Biomarker Testing Revenue by Application (2017-2028)
8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region
8.3.1 Asia-Pacific PD-L1 Biomarker Testing Revenue by Region (2017-2028)
8.3.2 China PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
8.3.3 Japan PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
8.3.4 South Korea PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
8.3.5 India PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
8.3.7 Australia PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America PD-L1 Biomarker Testing Revenue by Type (2017-2028)
9.2 South America PD-L1 Biomarker Testing Revenue by Application (2017-2028)
9.3 South America PD-L1 Biomarker Testing Market Size by Country
9.3.1 South America PD-L1 Biomarker Testing Revenue by Country (2017-2028)
9.3.2 Brazil PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
9.3.3 Argentina PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa PD-L1 Biomarker Testing Revenue by Type (2017-2028)
10.2 Middle East & Africa PD-L1 Biomarker Testing Revenue by Application (2017-2028)
10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country
10.3.1 Middle East & Africa PD-L1 Biomarker Testing Revenue by Country (2017-2028)
10.3.2 Turkey PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
10.3.4 UAE PD-L1 Biomarker Testing Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global PD-L1 Biomarker Testing Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global PD-L1 Biomarker Testing Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market PD-L1 Biomarker Testing Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global PD-L1 Biomarker Testing Revenue (USD Million) by Region (2017-2022)
Table 5. Global PD-L1 Biomarker Testing Revenue Market Share by Region (2023-2028)
Table 6. Agilent Technologies Corporate Information, Head Office, and Major Competitors
Table 7. Agilent Technologies Major Business
Table 8. Agilent Technologies PD-L1 Biomarker Testing Product and Solutions
Table 9. Agilent Technologies PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Roche Corporate Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche PD-L1 Biomarker Testing Product and Solutions
Table 13. Roche PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Merck Corporate Information, Head Office, and Major Competitors
Table 15. Merck Major Business
Table 16. Merck PD-L1 Biomarker Testing Product and Solutions
Table 17. Merck PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb PD-L1 Biomarker Testing Product and Solutions
Table 21. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca PD-L1 Biomarker Testing Product and Solutions
Table 25. AstraZeneca PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Ono Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 27. Ono Pharmaceutical Major Business
Table 28. Ono Pharmaceutical PD-L1 Biomarker Testing Product and Solutions
Table 29. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Regeneron Corporate Information, Head Office, and Major Competitors
Table 31. Regeneron Major Business
Table 32. Regeneron PD-L1 Biomarker Testing Product and Solutions
Table 33. Regeneron PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Innovent Corporate Information, Head Office, and Major Competitors
Table 35. Innovent Major Business
Table 36. Innovent PD-L1 Biomarker Testing Product and Solutions
Table 37. Innovent PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Hengrui Medicine Corporate Information, Head Office, and Major Competitors
Table 39. Hengrui Medicine Major Business
Table 40. Hengrui Medicine PD-L1 Biomarker Testing Product and Solutions
Table 41. Hengrui Medicine PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Junshi Biosciences Corporate Information, Head Office, and Major Competitors
Table 43. Junshi Biosciences Major Business
Table 44. Junshi Biosciences PD-L1 Biomarker Testing Product and Solutions
Table 45. Junshi Biosciences PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global PD-L1 Biomarker Testing Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global PD-L1 Biomarker Testing Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of PD-L1 Biomarker Testing by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. PD-L1 Biomarker Testing Players Head Office, Products and Services Provided
Table 50. PD-L1 Biomarker Testing Mergers & Acquisitions in the Past Five Years
Table 51. PD-L1 Biomarker Testing New Entrants and Expansion Plans
Table 52. Global PD-L1 Biomarker Testing Revenue (USD Million) by Type (2017-2022)
Table 53. Global PD-L1 Biomarker Testing Revenue Share by Type (2017-2022)
Table 54. Global PD-L1 Biomarker Testing Revenue Forecast by Type (2023-2028)
Table 55. Global PD-L1 Biomarker Testing Revenue by Application (2017-2022)
Table 56. Global PD-L1 Biomarker Testing Revenue Forecast by Application (2023-2028)
Table 57. North America PD-L1 Biomarker Testing Revenue by Type (2017-2022) & (USD Million)
Table 58. North America PD-L1 Biomarker Testing Revenue by Type (2023-2028) & (USD Million)
Table 59. North America PD-L1 Biomarker Testing Revenue by Application (2017-2022) & (USD Million)
Table 60. North America PD-L1 Biomarker Testing Revenue by Application (2023-2028) & (USD Million)
Table 61. North America PD-L1 Biomarker Testing Revenue by Country (2017-2022) & (USD Million)
Table 62. North America PD-L1 Biomarker Testing Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe PD-L1 Biomarker Testing Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe PD-L1 Biomarker Testing Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe PD-L1 Biomarker Testing Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe PD-L1 Biomarker Testing Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe PD-L1 Biomarker Testing Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe PD-L1 Biomarker Testing Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific PD-L1 Biomarker Testing Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific PD-L1 Biomarker Testing Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific PD-L1 Biomarker Testing Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific PD-L1 Biomarker Testing Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific PD-L1 Biomarker Testing Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific PD-L1 Biomarker Testing Revenue by Region (2023-2028) & (USD Million)
Table 75. South America PD-L1 Biomarker Testing Revenue by Type (2017-2022) & (USD Million)
Table 76. South America PD-L1 Biomarker Testing Revenue by Type (2023-2028) & (USD Million)
Table 77. South America PD-L1 Biomarker Testing Revenue by Application (2017-2022) & (USD Million)
Table 78. South America PD-L1 Biomarker Testing Revenue by Application (2023-2028) & (USD Million)
Table 79. South America PD-L1 Biomarker Testing Revenue by Country (2017-2022) & (USD Million)
Table 80. South America PD-L1 Biomarker Testing Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa PD-L1 Biomarker Testing Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa PD-L1 Biomarker Testing Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa PD-L1 Biomarker Testing Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa PD-L1 Biomarker Testing Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa PD-L1 Biomarker Testing Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa PD-L1 Biomarker Testing Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. PD-L1 Biomarker Testing Picture
Figure 2. Global PD-L1 Biomarker Testing Revenue Market Share by Type in 2021
Figure 3. PD-L1 (22C3)
Figure 4. PD-L1(28-8)
Figure 5. PD-L1 (SP142)
Figure 6. PD-L1 (SP263)
Figure 7. Other
Figure 8. PD-L1 Biomarker Testing Revenue Market Share by Application in 2021
Figure 9. Hospital Picture
Figure 10. Diagnostic Center Picture
Figure 11. Others Picture
Figure 12. Global PD-L1 Biomarker Testing Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global PD-L1 Biomarker Testing Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global PD-L1 Biomarker Testing Revenue Market Share by Region (2017-2028)
Figure 15. Global PD-L1 Biomarker Testing Revenue Market Share by Region in 2021
Figure 16. North America PD-L1 Biomarker Testing Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe PD-L1 Biomarker Testing Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific PD-L1 Biomarker Testing Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America PD-L1 Biomarker Testing Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa PD-L1 Biomarker Testing Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. PD-L1 Biomarker Testing Market Drivers
Figure 22. PD-L1 Biomarker Testing Market Restraints
Figure 23. PD-L1 Biomarker Testing Market Trends
Figure 24. Agilent Technologies Recent Developments and Future Plans
Figure 25. Roche Recent Developments and Future Plans
Figure 26. Merck Recent Developments and Future Plans
Figure 27. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 28. AstraZeneca Recent Developments and Future Plans
Figure 29. Ono Pharmaceutical Recent Developments and Future Plans
Figure 30. Regeneron Recent Developments and Future Plans
Figure 31. Innovent Recent Developments and Future Plans
Figure 32. Hengrui Medicine Recent Developments and Future Plans
Figure 33. Junshi Biosciences Recent Developments and Future Plans
Figure 34. Global PD-L1 Biomarker Testing Revenue Share by Players in 2021
Figure 35. PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players PD-L1 Biomarker Testing Revenue Market Share in 2021
Figure 37. Global Top 10 Players PD-L1 Biomarker Testing Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global PD-L1 Biomarker Testing Revenue Share by Type in 2021
Figure 40. Global PD-L1 Biomarker Testing Market Share Forecast by Type (2023-2028)
Figure 41. Global PD-L1 Biomarker Testing Revenue Share by Application in 2021
Figure 42. Global PD-L1 Biomarker Testing Market Share Forecast by Application (2023-2028)
Figure 43. North America PD-L1 Biomarker Testing Sales Market Share by Type (2017-2028)
Figure 44. North America PD-L1 Biomarker Testing Sales Market Share by Application (2017-2028)
Figure 45. North America PD-L1 Biomarker Testing Revenue Market Share by Country (2017-2028)
Figure 46. United States PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe PD-L1 Biomarker Testing Sales Market Share by Type (2017-2028)
Figure 50. Europe PD-L1 Biomarker Testing Sales Market Share by Application (2017-2028)
Figure 51. Europe PD-L1 Biomarker Testing Revenue Market Share by Country (2017-2028)
Figure 52. Germany PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific PD-L1 Biomarker Testing Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific PD-L1 Biomarker Testing Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific PD-L1 Biomarker Testing Revenue Market Share by Region (2017-2028)
Figure 60. China PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America PD-L1 Biomarker Testing Sales Market Share by Type (2017-2028)
Figure 67. South America PD-L1 Biomarker Testing Sales Market Share by Application (2017-2028)
Figure 68. South America PD-L1 Biomarker Testing Revenue Market Share by Country (2017-2028)
Figure 69. Brazil PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa PD-L1 Biomarker Testing Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa PD-L1 Biomarker Testing Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa PD-L1 Biomarker Testing Revenue Market Share by Country (2017-2028)
Figure 74. Turkey PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE PD-L1 Biomarker Testing Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
